Managing Toxicities and Shaping the Next 5 Years of Endometrial Cancer Care

In the final episode, ‘Managing Toxicities and Shaping the Next 5 Years of Endometrial Cancer Care,’ the panelists explored the following critical questions:

Which adverse events associated with immunotherapies should pharmacists be monitoring and managing in endometrial cancer?

How do you see the role of the pharmacist evolving in the next 5 years in the management of patients with endometrial cancer?

Led by the moderator, Megan May, the expert oncology pharmacists examined the "LEGS" acronym (Liver/Lung, Endocrine, GI, Skin) as a foundational framework for monitoring immune-related adverse events, while also noting the increased incidence of arthralgias when immunotherapy is added to chemotherapy. The panel discussed the evolving role of the pharmacist as a primary driver of biomarker testing, clinical trial enrollment for underrepresented populations, and the generation of real-world evidence through investigator-initiated trials. Jennifer MacDonald, Erin Zacholski, and Justina Salib reflected on the pharmacist’s unique position as a bridge between busy surgeons and patients, ensuring that toxicities are caught early—even when overachieving patients may be hesitant to report symptoms.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Thank you for watching this peer exchange series on endometrial cancer. Please subscribe to our newsletter for information on upcoming video series.